​

Revolution Medicines (RVMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RVMD Stock Forecast

Revolution Medicines (RVMD) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $253.47, with a high of $320.00 and a low of $179.00. This represents a 35.05% increase from the last price of $187.69.

$50 $110 $170 $230 $290 $350 High: $320 Avg: $253.47 Low: $179 Last Closed Price: $187.69

RVMD Stock Rating

Revolution Medicines stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 1 Strong Buy (4.00%), 22 Buy (88.00%), 2 Hold (8.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 2 22 1 Strong Sell Sell Hold Buy Strong Buy

RVMD Price Target Upside V Benchmarks

TypeNameUpside
StockRevolution Medicines35.05%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts62451
Avg Price Target$264.17$249.08$207.90
Last Closing Price$187.69$187.69$187.69
Upside/Downside40.75%32.71%10.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 265171--23
Sep, 264171--22
Aug, 264171--22
Jul, 264171--22
Jun, 264171--22
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 19, 2026Truist Financial$241.00$177.9635.42%28.40%
Oct 14, 2026RBC Capital$260.00$194.7833.48%38.53%
Oct 08, 2026RBC Capital$259.00$183.5241.13%37.99%
Oct 07, 2026Gregory RenzaTruist Financial$240.00$201.6519.02%27.87%
Sep 28, 2026Leah Rush CannLoop Capital Markets$318.00$204.9755.14%69.43%
Sep 24, 2026Goldman Sachs$267.00$190.7439.98%42.26%
Sep 10, 2026Sean LaamanMorgan Stanley$255.00$207.6822.79%35.86%
Sep 09, 2026Laura PrendergastStifel Nicolaus$230.00$207.3210.94%22.54%
Aug 31, 2026Needham$275.00$207.8832.29%46.52%
Aug 28, 2026UBS$265.00$221.1519.83%41.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2026GuggenheimBuyBuyhold
Oct 16, 2026William BlairMarket PerformOutperforminitialise
Oct 08, 2026Cowen & Co.BuyBuyhold
Oct 08, 2026RBC CapitalOutperformOutperformhold
Sep 28, 2026Brookline CapitalBuyinitialise
Sep 24, 2026Goldman SachsBuyBuyinitialise
Sep 10, 2026Morgan StanleyHoldOverweightinitialise
Sep 10, 2026Morgan StanleyOverweightHoldupgrade
Aug 31, 2026NeedhamBuyBuyhold
Aug 28, 2026UBSBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.47$-3.08$-3.86$-3.58$-5.95---
Avg Forecast$-2.50$-3.29$-3.48$-3.47$-3.93$-4.05$-3.71$-1.65
High Forecast$-2.50$-3.29$-3.29$-3.36$-3.72$-2.37$1.56$-1.65
Low Forecast$-2.50$-3.29$-3.77$-3.96$-4.58$-4.64$-6.12$-1.65
Surprise %-1.20%-6.38%10.92%3.17%51.40%---

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$29.39M$35.38M$11.58M-----
Avg Forecast$28.78M$27.86M$12.65M$300.00K$5.87M$19.77M$178.13M$589.38M
High Forecast$28.78M$27.86M$17.96M$300.00K$5.87M$19.77M$178.13M$589.38M
Low Forecast$28.78M$27.86M$11.52M$300.00K$5.87M$19.77M$178.13M$589.38M
Surprise %2.11%26.98%-8.47%-----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-187.09M$-248.71M$-436.37M$-600.09M$-1.13B---
Avg Forecast$-168.05M$-186.58M$-436.37M$-414.33M$-469.55M$-396.42M$-608.95M$-186.78M
High Forecast$-134.44M$-149.26M$-349.09M$-380.55M$-420.48M$-267.64M$176.54M$-186.78M
Low Forecast$-201.66M$-223.89M$-523.64M$-448.11M$-518.62M$-525.20M$-692.17M$-186.78M
Surprise %11.33%33.30%-44.83%140.93%---

RVMD Forecast FAQ

Is Revolution Medicines stock a buy?

Revolution Medicines stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 22 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Revolution Medicines is a favorable investment for most analysts.

What is Revolution Medicines's price target?

Revolution Medicines's price target, set by 25 Wall Street analysts, averages $253.47 over the next 12 months. The price target range spans from $179 at the low end to $320 at the high end, suggesting a potential 35.05% change from the previous closing price of $187.69.

How does Revolution Medicines stock forecast compare to its benchmarks?

Revolution Medicines's stock forecast shows a 35.05% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Revolution Medicines over the past three months?

  • October 2026: 21.74% Strong Buy, 73.91% Buy, 4.35% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 18.18% Strong Buy, 77.27% Buy, 4.55% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 18.18% Strong Buy, 77.27% Buy, 4.55% Hold, 0% Sell, 0% Strong Sell.

What is Revolution Medicines’s EPS forecast?

Revolution Medicines's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.05, marking a -31.93% decrease from the reported $-5.95 in 2025. Estimates for the following years are $-3.71 in 2027, and $-1.65 in 2028.

What is Revolution Medicines’s revenue forecast?

Revolution Medicines's average annual revenue forecast for its fiscal year ending in December 2026 is $19.77M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $178.13M, and $589.38M for 2028.

What is Revolution Medicines’s net income forecast?

Revolution Medicines's net income forecast for the fiscal year ending in December 2026 stands at $-396M, representing a -64.96% decrease from the reported $-1.131B in 2025. Projections indicate $-609M in 2027, and $-187M in 2028.